Open-label, Dose-escalation, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Myocardial Territory With Incomplete Revascularization During Coronary Artery Bypass Graft in Patients With Ischemic Heart Disease

Trial Profile

Open-label, Dose-escalation, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Myocardial Territory With Incomplete Revascularization During Coronary Artery Bypass Graft in Patients With Ischemic Heart Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Ischaemic heart disorders
  • Focus Adverse reactions
  • Sponsors ViroMed
  • Most Recent Events

    • 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top